
Fractional exhaled nitric oxide (FeNO) is a non‐invasive biomarker that reflects IL‐4/IL‐13 production and therefore represents T2 allergic inflammation. FeNO has previously been used to guide inhaled corticosteroid (ICS) treatment in asthma. The purpose of this study was to determine if a low FeNO (≤27 ppb) could be used to reliably identify patients with symptoms suggestive of asthma who would not benefit from initiating treatment with an ICS...
Like
Save
Share